Goldenwell Biotech, Inc. (GWLL)

Market Cap	267.30M
Revenue (ttm)	37.34K
Net Income (ttm)	-90.20K
Shares Out	99.00M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,065
Average Volume	5,193
Open	1.990
Previous Close	1.500
Day's Range	1.990 - 2.990
52-Week Range	0.200 - 2.700
Beta	2.09
RSI	89.08
Earnings Date	Nov 26, 2025

About Goldenwell Biotech

Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2019
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: GWLL

Financial Performance

In 2024, Goldenwell Biotech's revenue was $139, a decrease of -92.43% compared to the previous year's $1,836. Losses were -$131,498, 12.0% more than in 2023.